Current prodrug strategies for improving oral absorption of nucleoside analogues

Asian Journal of Pharmaceutical Sciences

Volumn 9, Issue 2, 2014, Pages 65-74

  Zhang, Youxi ^a   Gao, Yikun ^b   Wen, Xiaojing ^a   Ma, Haiying ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Nucleoside analogues; Oral bioavailability; Prodrug

Indexed keywords

2' DEOXY 2' FLUORO 2' METHYLCYTIDINE; 3 [4 HYDROXY 5 (HYDROXYMETHYL)TETRAHYDROFURAN 2 YL] 6 (4 PENTYLPHENYL)FURO[2,3 D]PYRIMIDIN 2 ONE; 5' O LEVO VALYLESTER; ABACAVIR; ABACAVIR PHOSPHORAMIDATE; ACICLOVIR; ADEFOVIR; ADEFOVIR DIPIVOXIL; CARBOVIR; CIDOFOVIR; DIDANOSINE; DIPEPTIDYL PEPTIDASE IV; ESTER; FAMCICLOVIR; GANCICLOVIR; GEMCITABINE; LAGOCICLOVIR; MERICITABINE; NUCLEOSIDE ANALOG; PENCICLOVIR; PRODRUG; RIBAVIRIN; TARIBAVIRIN; TENOFOVIR DISOPROXIL; TETRAPEPTIDE AMIDE; TRIPEPTIDE ESTER; UNCLASSIFIED DRUG; VALACICLOVIR; VALGANCICLOVIR; VALYLOXYPROPYLESTER; VILDAGLIPTIN;

AREA UNDER THE CURVE; CHEMICAL MODIFICATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TRANSPORT; HUMAN; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; REVIEW;

EID: 84919785501     PISSN: 18180876     EISSN: 2221285X     Source Type: Journal    
DOI: 10.1016/j.ajps.2013.12.006     Document Type: Review

References (91)

1. Balimane P.V., Sinko P.J. Involvement of multiple transporters in the oral absorption of nucleoside analogues. Adv Drug Deliv Rev 1999, 39:183-209.
2. Lalanne M., Andrieux K., Couvreur P. Strategies to increase the oral bioavailability of nucleoside analogs. Curr Med Chem 2009, 16:1391-1399.
3. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004, 30:115-133.
4. Rideout J.L., Henry D.W., Beacham L.M. Nucleosides, nucleotides, and their biological applications. Proceedings of the 5th International Round Table, October 20-22, 1982 1983, Academic Press, New York.
5. Li F.J., Maag H., Alfredson T. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J Pharm Sci 2008, 97:1109-1134.
6. Lalezari J.P., Friedberg D.N., Bissett J., et al. High dose oral ganciclovir treatment for cytomegalovirus retinitis. J Clin Virol 2002, 24:67-77.
7. Cundy K.C. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet 1999, 36:127-143.
8. Collins J.M., Klecker R.W., Kelley J.A., et al. Pyrimidine dideoxyribonucleosides: selectivity of penetration into cerebrospinal fluid. J Pharmacol Exp Ther 1988, 245:466-470.
9. Gustavson L.E., Fukuda E.K., Rubio F.A., et al. A pilot study of the bioavailability and pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS or AIDS-related complex. J Acquir Immune Defic Syndr 1990, 3:28-31.
10. Klecker R.W., Collins J.M., Yarchoan R., et al. Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 1987, 41:407-412.
11. Knupp C.A., Shyu W.C., Dolin R., et al. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin Pharmacol Ther 1991, 49:523-535.
12. Richman D.D., Fischl M.A., Grieco M.H., et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987, 317:192-197.
13. Yarchoan R., Mitsuya H.J., Pluda M., et al. The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles. Rev Infect Dis 1990, 12:522-533.
14. Weller S., Blum M.R., Doucette M., et al. Pharmacokinetics of the acyclovir prodrug valaciclovir after escalating single- and multiple-dose administration to normal volunte. Clin Pharmacol Ther 1993, 54:595-605.
15. Steingrimsdottir H., Gruber A., Palm C., et al. Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy. Antimicrob Agents Chemother 2000, 44:207-209.
16. De Vrueh R.L.A., Smith P.L., Lee C.P. Transport of l-valine-acyclovir via the oligopeptide transporter in the human intestinal cell line, Caco-2. J Pharmacol Exp Ther 1998, 286:1166-1170.
17. Balimane P.V., Tamai I., Guo a, et al. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem Biophys Res Commun 1998, 250:246-251.
18. Kim I., Chu X.-Y., Kim S., et al. Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. J Biol Chem 2003, 278:25348-25356.
19. Puente X.S., López-Otn C. Cloning and expression analysis of a novel human serine hydrolase with sequence similarity to prokaryotic enzymes involved in the degradation of aromatic compounds. J Biol Chem 1995, 270:12926-12932.
20. Hu M., Subramanian P., Mosberg H.I., et al. Use of the peptide carrier system to improve the intestinal absorption of l-α-methyldopa: carrier kinetics, intestinal permeabilities, and invitro hydrolysis of dipeptidyl derivatives of l-α-methyldopa. Pharm Res 1989, 6:66-70.
21. Nashed Y. Synthesis and characterization of novel dipeptide ester prodrugs of acyclovir. Spectrochim Acta A 2003, 59:2033-2039.
22. Anand B.S., Patel J., Mitra A.K. Interactions of the dipeptide ester prodrugs of acyclovir with the intestinal oligopeptide transporter: competitive inhibition of glycylsarcosine transport in human intestinal cell. Pharmacology 2003, 304:781-791.
23. Anand B.S., Katragadda S., Mitra A.K. Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism. Pharmacology 2004, 311:659-667.
24. Fox D.A., Hussey R.E., Fitzgerald K.A., et al. Ta1, a novel 105 kDa human T cell activation antigen defined by a monoclonal antibody. J Immunol 1984, 133:1250-1256.
25. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999, 85:9-24.
26. Mentlein R. Cell-surface peptidases. Int Rev Cytol 2004, 235:165-202.
27. Diez-Torrubia A., Cabrera S., Castro S., et al. Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidylpeptidase IV (DPP IV/CD26) enzyme. Eur J Med Chem 2013, 70:456-468.
28. Biron K.K. Antiviral drugs for cytomegalovirus diseases. Antivir Res 2006, 71:154-163.
29. Leibach F.H., Ganapathy V., Ganapathy M.E. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci 2000, 89:781-789.
30. Cvetkovic R.S., Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs 2005, 65:859-878.
31. Perry C.M., Nobel S. Didanosine - an updated review of its use in HIV infection. Drugs 1999, 58:1099-1135.
32. Singhal D., Ho N.F., Anderson B.D. Absorption and intestinal metabolism of purine dideoxynucleosides and an adenosine deaminaseactivated prodrug of 20,3-dideoxyinosine in the mesenteric vein cannulated rat ileum. J Pharm Sci 1998, 87:569-577.
33. Anderson B.D., Morgan M.E., Singhal D. Enhanced oral bioavailability of DDI after administration of 6-Cl-ddP, an adenosine deaminase-activated prodrug, to chronically catheterized rats. Pharm Res 1995, 12:1126-1133.
34. Sriram D., Yogeeswari P., Babu N.R., et al. Synthesis and invitro anti-HIV activities of didanosine prodrugs. J Enzyme Inhib Med Chem 2007, 22:51-55.
35. Yan Z.T., Sun J., Chang Y.N., et al. Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics. Mol Pharm 2011, 8:319-329.
36. Boyd M.R., Bacon T.H., Sutton D., et al. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother 1987, 31:1238-1242.
37. Morse G.D., Shelton M.J., O'Donnell A.M. Comparative pharmacokinetics of antiviral nucleoside analogues. Clin Pharmacokinet 1993, 24:101-123.
38. Vere Hodge R.A. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antivir Chem Chemother 1993, 4:67-84.
39. Rashidi M.R., Smith J.A., Clarke S.E., et al. Invitro oxidation of famciclovir and 6-eoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metab Dispos 1997, 25:805-813.
40. Perry C.M., Wagstaff A.J. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infection. Drugs 1995, 50:396-415.
41. Pue M.A., Benet L.Z. Pharmacokinetics of famciclovir in man. Antivir Chem Chemother 1993, 4:47-55.
42. Kim D.K., Lee N., Kim Y.W., et al. Synthesis and evaluation of 2-amino-9-(3-hydroxymethyl-4-alkoxycarbonyloxybut-1-yl)purines as potential prodrugs of penciclovir. J Med Chem 1998, 41:3435-3441.
43. Murakami E., Bao H., Ramesh M., et al. Mechanism of activation of b-d-2'-deoxy-2'-fluoro-2'-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob Agents Chemother 2007, 51:503-509.
44. McHutchison J.G., Reddy R., Rodriguez-Torres M., et al. Potent antiviral activity of the nucleoside HCV inhibitor, R7128, in prior IFN nonresponders. Presented at: Frontiers in Drug Development in Viral Hepatitis (HEP-DART). Lahaina, Hawaii, USA December 2007, 9-13.
45. Pharmasset. http://www.pharmasset.com/pipeline/rg7128.aspx.
46. McGuigan C., Yarnold C.J., Jones G., et al. Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base. J Med Chem 1999, 42:4479-4484.
47. McGuigan C., Barucki H., Blewett S., et al. Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain. J Med Chem 2000, 43:4993-4997.
48. McGuigan C., Pathirana R.N., Migliore M., et al. Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus. J Antimicrob Chemother 2007, 60:1316-1330.
49. Alberto D.-T., Jan B., Graciela A., et al. Dipeptidyl peptidase IV dependent water-soluble prodrugs of highly lipophilic bicyclic nucleoside analogues. J Med Chem 2011, 54:1927-1942.
50. Leng L.Y., Cai Z.Q., Sun T.M. Strategy in the study of nucleoside antiviral prodrugs. Chin J Med Chem 2008, 118:310-316.
51. Bronson J.J., Ho H.T., Boeck H.D., et al. Biochemical pharmacology of acyclic nucleotide analogues. Ann NY Acad Sci 1990, 616:398-407.
52. Krise J.P., Stella V.J. Prodrugs of phosphates, phosphonates, and phosphinates. Adv Drug Deliv Rev 1996, 19:287-310.
53. Meier C. Pro-nucleotides-recent advances in the design of efficient tools for the delivery of biologically active nucleoside monophosphates. Synlett 1998, 3:233-242.
54. Wachsman M., Petty B.G., Cundy K.C., et al. Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. Antivir Res 1996, 29:153-161.
55. Naesens L., Bischofberger N., Augustijns P., et al. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl) adenine in mice. Antimicrob Agents Chemother 1998, 42:1568-1573.
56. Starrett J.E., Tortolani D.R., Russell J., et al. Synthesis, oralbioavailability determination, and invitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). J Med Chem 1994, 37:1857-1864.
57. Annaert P., Kinget R., Naesens L., et al. Transport, uptake, and metabolism of the bis(pivaloyloxymethyl)-ester prodrugs of 9-(2-phosphonylmethoxyethyl) adenine in an invitro cell culture system of the intestinal mucosa (Caco-2). Pharm Res 1997, 14:492-496.
58. Barditch-Crovo P., Toole J., Hendrix C.W., et al. Antihuman immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-(pivaloyloxymethyl)-phosphonylmethoxyethyl] adenine) in HIV infected patients. J Inf Dis 1997, 176:406-413.
59. Dando T.M., Plosker G.L. Adefovir dipivoxil. Drugs 2003, 63:2215-2234.
60. Lalezari J.P., Stagg R.J., Kuppermann B.D., et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS: a randomized, controlled trial. Ann Pathol Lab Med 1997, 124:362-377.
61. Mendel D.B., Cihlar T., Moon K., et al. Conversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl) methyl] cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase. J Antimicrob Agents Chemother 1997, 41:641-646.
62. Ciesla S.L., Trahan J., Wan W.B., et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes accumulation in kidney. Antivir Res 2003, 59:163-171.
63. Painter G.R., Hostetler K.Y. Design and development of oraldrugs for the prophylaxis and treatment of smallpox infection. TRENDS Biotechnol 2004, 22:423-427.
64. Parker S., Touchette E., Oberle C., et al. Efficacy of therapeuticintervention with an oral ether-lipid analogue ofcidofovir (CMX001) in a lethal mousepox model. Antivir Res 2008, 77:39-49.
65. Quenelle D.C., Collins D.J., Wan W.B., et al. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004, 48:404-412.
66. Keith K.A., Wan W.B., Ciesla S.L., et al. Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication invitro. Antimicrob Agents Chemother 2004, 48:1869-1871.
67. Aldern K.A., Ciesla S.L., Winegarden K.L., et al. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-14C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol Pharmacol 2003, 63:678-681.
68. Eriksson U., Peterson L.W., Kashemirov B.A., et al. Mol Pharm 2008, 5:598-609.
69. Tehlera U., Nelsona C.H., Petersonc L.W., et al. Amidona puromycin-sensitive aminopeptidase: an antiviral prodrug activating enzyme. Antivir Res 2010, 85:482-489.
70. Arimilli M.N., Kim C.U., Dougherty J., et al. Synthesis, invitrobiological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy)-propyl]adenine (PMPA) prodrugs. Antivir Chem Chemother 1997, 8:557-564.
71. Shaw J.P., Sueoka C.M., Oliyai R., et al. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm Res 1997, 14:1824-1829.
72. Barditch-Crovo P., Deeks S.G., Dollier A., et al. Phase I/II trial of the pharmacokinetics, safety, and antiviral activity of tenofovir dioproxil fumarate in human immunodeficiency virus infected adults. Antimicrob Agents Chemother 2001, 45:2733-2739.
73. McGuigan C., Pathirana R.N., Mahmood N., et al. Aryl phosphates derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT. Antivir Res 1992, 17:311-321.
74. Balzarini J., Aquaro S., Hassan-Abdallah A., et al. Improvedantiviral activity of the aryloxymethoxyalaninyl phosphoramidate (APA) prodrug of abacavir (ABC) isdueto the formation of markedly increased carbovir 5'-triphosphate metabolite levels. FEBS Lett 2004, 573:38-44.
75. Lee W.A., He G.X., Eisenberg E., et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother 2005, 49:1898-1906.
76. Cahard D., McGuigan C., Balzarini J. Aryloxy phosphoramidate triesters as protides. Mini Rev Med Chem 2004, 4:371-381.
77. McGuigan C., Harris S.A., Daluge S.M., et al. Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency. J Med Chem 2005, 48:3504-3515.
78. Toschi L., Finocchiaro G., Bartolini S., et al. Role of gemcitabine in cancer therapy. Future Oncol 2005, 1:7-17.
79. Bergman A.M., Pinedo H.M., Peters G.J. Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 2002, 5:19-33.
80. Myhren F, Borretzen B, Dalen A, et al. EP0986570, 2000.
81. Couvreur P., Stella B., Reddy L.H., et al. Squalenoyl nanomedicines as potential therapeutics. Nano Lett 2006, 6:2544-2548.
82. Wickremsinhe E., Bao J.Q., Smith R., et al. Preclinical absorption, distribution, metabolism, and excretion of an oral amide prodrug of gemcitabine designed to deliver prolonged systemic exposure. Pharmaceutics 2013, 5:261-276.
83. Yamamoto N., Nokihara H., Yamada Y., et al. Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2013, 71:1645-1655.
84. Daluge S.M., Good S.S., Faletto M.B., et al. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother 1997, 41:1082-1093.
85. Chittick G.E., Gillotin C., McDowell J.A., et al. Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food. Pharmacotherapy 1999, 19:932-942.
86. Faletto M.B., Miller W.H., Garvey E.P., et al. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592 U89. Antimicrob Agents Chemother 1997, 41:1099-1107.
87. Wu J.Z., Lin C.C., Hong Z. Ribavirin, viramidine and adenosine-deaminase-catalysed drug activation: Implication for nucleoside prodrug design. J Antimicrob Chemother 2003, 52:543-546.
88. Lin C.C., Luu K., Lourenco D., et al. Pharmacokinetics and metabolism of [14C] viramidine in rats and cynomolgus monkeys. Antimicrob Agents Chemother 2003, 47:2458-2463.
89. Lin C.C., Xu C., Zhu N., et al. Absorption, metabolism, and excretion of [14C] viramidine in humans. Antimicrob Agents Chemother 2006, 50:2368-2373.
90. Lin C.C., Yeh L.T., Vitarella D., H., et al. Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. Antivir Chem Chemother 2003, 14:145-152.
91. Benhamou Y., Pockros P., Rodriguez-Torres M., et al. The safety and efficacy of viramidine plus pegylated interferon alpha-2b versus ribavirin plus pegylated interferon alpha-2b in therapy-naïve patients infected with HCV phase 3 results. J Hepatol 2006, 44:S273.